Literature DB >> 21097517

Neurovascular coupling in the human visual cortex is modulated by cyclooxygenase-1 (COX-1) gene variant.

Tim Hahn1, Sebastian Heinzel, Michael M Plichta, Andreas Reif, Klaus-Peter Lesch, Andreas J Fallgatter.   

Abstract

Functional hyperemia, the brain's capability to alter microvascular blood flow in response to the metabolic demands of active neurons, is essential for sustained mammalian brain function. Pharmacological studies in mice suggest neurovascular coupling to centrally involve cyclooxygenase-1 (COX-1) metabolites such as prostaglandins. In humans, however, genetic variation of the COX-1 gene impacting the coupling of neural activity to hemodynamic responses (HRs) has not been investigated yet. In this study, we determined whether COX-1 genotype-dependent enzymatic function impacts HRs in humans. Specifically, using a double-blind Imaging Genetics approach utilizing functional near-infrared spectroscopy, we measured HRs following visual checkerboard stimulation. COX-1 genotype (L237M, rs5789)-dependent decrease in enzymatic function in heterozygous L/M carriers is associated with a 42% reduction of the HR amplitude. This finding is discussed in the context of potentially imbalanced neurovascular mechanisms involving arachidonic acid, which underlie vasodilatory and vasoconstrictive forces of functional hemodynamics. Generally, these findings might help to improve our understanding of pathologies such as stroke and Alzheimer's disease in which neurovascular coupling is altered. Additionally, our results may have important implications for functional brain imaging in which HRs are commonly used as a surrogate for neural activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097517     DOI: 10.1093/cercor/bhq236

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  7 in total

1.  Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging.

Authors:  Danny J J Wang; Yufen Chen; María A Fernández-Seara; John A Detre
Journal:  J Pharmacol Exp Ther       Date:  2011-02-11       Impact factor: 4.030

Review 2.  The continuing challenge of understanding and modeling hemodynamic variation in fMRI.

Authors:  Daniel A Handwerker; Javier Gonzalez-Castillo; Mark D'Esposito; Peter A Bandettini
Journal:  Neuroimage       Date:  2012-02-14       Impact factor: 6.556

Review 3.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

4.  Molecular hydrogen alleviates asphyxia-induced neuronal cyclooxygenase-2 expression in newborn pigs.

Authors:  Viktória Varga; János Németh; Orsolya Oláh; Valéria Tóth-Szűki; Viktória Kovács; Gábor Remzső; Ferenc Domoki
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

5.  Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1.

Authors:  Wen Liu; Elizabeth M Poole; Cornelia M Ulrich; Richard J Kulmacz
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

6.  Genes influence the amplitude and timing of brain hemodynamic responses.

Authors:  Zuyao Y Shan; Anna A E Vinkhuyzen; Paul M Thompson; Katie L McMahon; Gabriëlla A M Blokland; Greig I de Zubicaray; Vince Calhoun; Nicholas G Martin; Peter M Visscher; Margaret J Wright; David C Reutens
Journal:  Neuroimage       Date:  2015-09-12       Impact factor: 6.556

7.  A novel approach to probabilistic biomarker-based classification using functional near-infrared spectroscopy.

Authors:  Tim Hahn; Andre F Marquand; Michael M Plichta; Ann-Christine Ehlis; Martin W Schecklmann; Thomas Dresler; Tomasz A Jarczok; Elisa Eirich; Christine Leonhard; Andreas Reif; Klaus-Peter Lesch; Michael J Brammer; Janaina Mourao-Miranda; Andreas J Fallgatter
Journal:  Hum Brain Mapp       Date:  2012-01-16       Impact factor: 5.038

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.